تعديل

lundi 7 décembre 2015

Novartis says CART study findings bolster 2017 approval case

ZURICH (Reuters) - More than 90 percent of young people with a deadly form of blood cancer showed complete remission after getting a new Novartis therapy, mirroring findings from previous smaller samples and buoying the drugmaker's hopes for U.S. approval in 2017.


http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro

Aucun commentaire:

Enregistrer un commentaire